The company's vd Yep Ovlesen and CMO Other Dyhr Tough visited BioStocks studio - for to tell me more about study results and what awaits next.
Watch the interview with SynAct Pharmas vd Jeppe Øvlesen and CMO Anders Dyhr Toft below.
SynAct Pharma has presented top line results from BEGIN, a phase IIa study with the drug candidate AP1189 in rheumatoid arthritis.
The company's vd Yep Ovlesen and CMO Other Dyhr Tough visited BioStocks studio - for to tell me more about study results and what awaits next.
Watch the interview with SynAct Pharmas vd Jeppe Øvlesen and CMO Anders Dyhr Toft below.